Semaglutide Oral (Rybelsus)

Semaglutide: drug concentration in plasma (nmol/L).

Oral study example; absorption varies between doses. Not a personal or population-average prediction.

Fixed reference profile: Healthy 85 kg adult without type 2 diabetes; fixed published reference parameters, not an average patient. Original oral semaglutide/SNAC formulation studied with 300 mg SNAC; first-generation Rybelsus context, not newer oral formulations; Oral tablet. Fixed reference weight: 85 kg.

Changing dose or schedule explores a scenario; it does not personalize the reference profile or establish a studied regimen.

Input dose basis: Milligrams of semaglutide in the original oral tablet formulation; no tablet splitting, product substitution or oral-to-injected conversion is implied.

Source exposure scope: The main oral model used 5–10 mg clinical-pharmacology inputs. In this healthy reference, 7 mg is interpolation; 3 mg and 14 mg are extrapolations despite being original Rybelsus tablet strengths.

Oral study reference: healthy 85 kg adult, fixed dosing conditions

oral-semaglutide-overgaard-2021-healthy-reference · version 1

• Administration in a fasting state with 50–120 mL plain water and exactly 30 minutes of post-dose fasting; these conditions stay fixed for every simulated dose.
• Oral availability is fixed at 0.795% (fraction 0.00795) and applied once. Food, water volume and absorption changes are not inferred from the entered schedule.
• Between-person and dose-to-dose random effects are zero. The source’s large absorption variability and population prediction intervals are not simulated.
• No semaglutide is present before the entered dose history. No diabetes, body-weight or off-site dosing covariate adjustment is applied.

Model structure

Two compartments with absorption

Clearance (CL)

0.0348 L/hour

Central volume (Vc)

3.59 L

Absorption rate (ka)

2.09 /hour

Intercompartmental clearance (Q)

0.304 L/hour

Peripheral volume (Vp)

4.1 L

Bioavailability (F)

0.795%

Input mass conversion

1 mg modelled mass per mg entered

• This fixed study example omits substantial dose-to-dose absorption variability. It is neither an individual prediction nor a reproduction of the source population-average profile.
• At 7 mg daily this reference approaches a mean of about 16.2 nmol/L; the Rybelsus label reports 6.7 nmol/L in its T2D population. These different contexts must not be interchanged or fitted together.
• Changing fasting duration, food, water volume or coadministered tablets can change absorption. The model does not adjust for those changes.
• Newer Ozempic or Wegovy tablets, injected semaglutide and compounded preparations are outside this formulation scope.
• Concentration is not a prediction of glucose response, weight loss, tolerability or a safe dose; clearance thresholds are not safety or testing guarantees.

• Overgaard et al. 2021 — clinical pharmacokinetics of oral semaglutide

  Equations 1–12 and Table 2 establish the oral two-compartment context. Section 2.5 warns that ordinary fixed-reference predictions do not represent population profiles when dose-to-dose absorption varies greatly.

• Overgaard et al. 2021 — supplementary model parameters

  Online-resource Table 1 supplies CL 0.0348 L/h, Vc 3.59 L, Q 0.304 L/h, Vp 4.1 L, oral ka 2.09/h and F 0.795%. All weight factors equal one at 85 kg; healthy status leaves the diabetes factor off.

• Novo Nordisk Rybelsus and Ozempic tablets prescribing information

  Sections 2.1, 11 and 12.3: formulation-specific administration, molecular weight 4113.58 g/mol and distinct tablet bioavailability. The label’s T2D population means are not this healthy fixed-reference curve.